Regulus Therapeutics (NASDAQ:RGLS)‘s stock had its “neutral” rating restated by investment analysts at Chardan Capital in a research report issued to clients and investors on Tuesday.
RGLS has been the subject of a number of other research reports. Zacks Investment Research upgraded shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a research note on Tuesday, October 10th. Needham & Company LLC restated a “hold” rating on shares of Regulus Therapeutics in a research note on Tuesday, November 14th. Leerink Swann initiated coverage on shares of Regulus Therapeutics in a research note on Friday, January 5th. They issued an “outperform” rating and a $2.00 price target for the company. Finally, Wedbush restated an “outperform” rating and issued a $4.00 price target on shares of Regulus Therapeutics in a research note on Monday, December 11th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company. Regulus Therapeutics currently has an average rating of “Hold” and an average price target of $2.46.
Shares of Regulus Therapeutics (NASDAQ:RGLS) opened at $1.40 on Tuesday. The company has a current ratio of 6.77, a quick ratio of 6.77 and a debt-to-equity ratio of 0.41. Regulus Therapeutics has a 12 month low of $0.79 and a 12 month high of $2.45.
A number of hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada increased its stake in Regulus Therapeutics by 12.1% during the second quarter. Royal Bank of Canada now owns 184,040 shares of the biopharmaceutical company’s stock valued at $182,000 after purchasing an additional 19,934 shares during the last quarter. FMR LLC increased its stake in Regulus Therapeutics by 0.5% during the second quarter. FMR LLC now owns 7,977,349 shares of the biopharmaceutical company’s stock valued at $7,862,000 after purchasing an additional 37,489 shares during the last quarter. GSA Capital Partners LLP increased its stake in Regulus Therapeutics by 44.8% during the third quarter. GSA Capital Partners LLP now owns 203,815 shares of the biopharmaceutical company’s stock valued at $255,000 after purchasing an additional 63,100 shares during the last quarter. Quantitative Investment Management LLC bought a new stake in Regulus Therapeutics during the second quarter valued at $103,000. Finally, Goldman Sachs Group Inc. increased its stake in Regulus Therapeutics by 189.1% during the second quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock valued at $363,000 after purchasing an additional 240,890 shares during the last quarter. Hedge funds and other institutional investors own 59.39% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Regulus Therapeutics (RGLS) Earns “Neutral” Rating from Chardan Capital” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/01/20/regulus-therapeutics-rgls-earns-neutral-rating-from-chardan-capital.html.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.